Among the 47.2% of patients who had twice-daily radiation, median overall survival was 35.4 months vs 28.3 months in those who received once-daily radiation (HR, 1.44; 95% CI, 1.10-1.89).

The latest data, which included a small cohort of 30 patients, revealed that adding low-dose radiation to the standard first-line therapy led to a higher median progression-free survival of 8.3 ...

In a phase 2 trial, Mass General Brigham researchers found patients were successfully treated with targeted radiation rather than the historical standard of whole brain radiation. A new study led by ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent ...

Treatment of limited-stage small cell lung cancer (LS-SCLC) with twice-a-day radiation therapy (RT) has remained the standard of care for many decades. Growing evidence suggests that outcomes with ...

The St. Helena-based VeriTainer Corp. reached a milestone Nov. 15 when its CEO, John Alioto, announced during a press conference that the company would commence a 60-day trial of its ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the ...

The Department of Homeland Security plans to use the Port of Tacoma to test different ways of scanning cargo containers for radiation and other dangerous emissions at U.S. ports.

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent ...